SavedAdd your journal

Journals / GORM:Gynecology Obstetrics & Reproductive Medicine / 2016 / Cilt: 22 - Sayı: 2

Problems and Complications During the Treatment of Infertility in Women with Polycystic Ovary Syndrome

MÜBERRA NAMLI KALEM
ZİYA KALEM
Timur GÜRGAN
Pages
113–124
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, even if these conditions are provided, OHSS, cancellations of the cycle, pooroocyte, and embryo qualities, unsuccessful fertilization and implantation, chromosomal abnormalitiesand early losses may still be experienced.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder existing in women in theirreproductive years and it is one of the most evaluated and discussed subjects of reproductive medicinewith regard to its diagnosis and treatment.Patients with PCOS constitute the most difficult population in the management of infertility.
📊
Key Findings & Data:The factorsthat increase the success rates in the treatment of PCOS infertility are: pretreatment changes in lifestyle, dietetic and psychological support, a detailed evaluation of the couple and the appropriate selection of the treatment protocol, a wide-spectrum approach to maintaining ovarian and endometrial synchronization in the management of the cycle, and well-developed laboratory conditions to support embryonic quality.
💡
Conclusion & Impact:However, even if these conditions are provided, OHSS, cancellations of the cycle, pooroocyte, and embryo qualities, unsuccessful fertilization and implantation, chromosomal abnormalitiesand early losses may still be experienced.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder existing in women in theirreproductive years and it is one of the most evaluated and discussed subjects of reproductive medicinewith regard to its diagnosis and treatment.Patients with PCOS constitute the most difficult population in the management of infertility. The factorsthat increase the success rates in the treatment of PCOS infertility are: pretreatment changes in lifestyle, dietetic and psychological support, a detailed evaluation of the couple and the appropriate selection of the treatment protocol, a wide-spectrum approach to maintaining ovarian and endometrial synchronization in the management of the cycle, and well-developed laboratory conditions to support embryonic quality. However, even if these conditions are provided, OHSS, cancellations of the cycle, pooroocyte, and embryo qualities, unsuccessful fertilization and implantation, chromosomal abnormalitiesand early losses may still be experienced.

🔖

Cite This Article

KALEM, M. N., KALEM, Z., GÜRGAN, T. (2016). Problems and Complications During the Treatment of Infertility in Women with Polycystic Ovary Syndrome. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 22 - Sayı: 2, 113–124. https://ajindex.com/articles/190628

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Fauser BCJM. Tarlatzis BC. Rebar RW. Legro RS. Balen AH. Lobo R. & Barnhart K. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Human Reproduction 2012;27;(1):14-24. Dunaif A. and Fauser BC. Renaming PCOS-a two-state solution. The Journal of Clinical Endocrinology & Metabolism 2013;98(11):4325-8. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consen sus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
  2. Eshre TT. Group, ASPCW. Consensus on infertility treat- ment related to polycystic ovary syndrome. Fertility and sterility 2008;89(3):505-22.
  3. MacDougall MJ, Tan SL, et al. A controlled study com- paring patients with and without polycystic ovaries under- going in-vitro fertilization. Hum Reprod 1993;8:233-7 Lyons CAD. Wheeler CA. Frishman GN. Hackett RJ. Seifer DB. Haning RV. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors.Human Reproduction 1994; 9(5):792-9. Humaidan P. Quartarolo J. Papanikolaou EG. Preven ting ovarian hyperstimulation syndrome: guidance for the cli- nician. Fertility and sterility 2010;94(2):389-400.
  4. Shulman A, Dor J. In vitro fertilization treatment in pa- tients with polycystic ovaries. J Assist Reprod Genet 1997;14:7-10.
  5. Kamat BR, Brown LF, Manseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol 1995;146:157-65.
  6. Danninger B, Brunner M, Obruca A, Feichtinger W. Prediction of ovarian hyperstimulation syndrome by ultra- sound volumetric assessment [corrected] of baseline ovar- ian volume prior to stimulation. Hum Reprod 1996;11: 1597-9.
  7. Moohan JM, Curcio K, Leoni M, Healy D, Hurley V. Low intraovarian vascular resistance: a marker for severe ovarian hyperstimulation syndrome. Fertil Steril 1997;67:728-32.
  8. Bodis J, Torok A, Tinneberg HR. LH/FSH ratio as a pre- dictor of ovarian hyperstimulation syndrome. Hum Reprod 1997;12:869-70.
  9. Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, et al. Serum anti-mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in as- sisted reproduction technology cycles. Hum Reprod 2008;23:160-7. Papanikolaou EG. Humaidan P. Polyzos N. Kalantaridou S. Kol S. Benadiva C. Tarlatzis B. New algorithm for OHSS prevention. Reprod Biol Endocrinol 2011;9